This Nature section is another excellent statistics reference: https://t.co/HWK66QyHOb https://t.co/5DJqZshRO3
— David Sable (@dbsable) November 2, 2016
Cardiac Toxicity from Combination Immune Checkpoint Inhibitorshttps://t.co/yAWgX9Y8rT$BMY $MRK $AZN $RHHBY pic.twitter.com/RjCczmIvrN
— Andy Biotech (@AndyBiotech) November 3, 2016
Great review here of Ph 2 & Ph 3 failures. Puts risk/reward into proper perspective! https://t.co/QRalzIF4OH
— Sheff (@SheffStation) November 4, 2016
A CRISPR-based methodology for correcting β-globin gene mutations in haematopoietic stem cells https://t.co/GZk9U2kpt6 pic.twitter.com/viRPL0d2MS
— nature (@nature) November 8, 2016
As we age, our #brain is steadily deteriorating :-( Can it be prevented? A nice #OA review https://t.co/bi8FvIUO4f pic.twitter.com/5LxAUeQf4a
— Eric Topol (@EricTopol) November 14, 2016
This was a cool paper:
— Dan Marks (@Festivus159) November 18, 2016
De novo design of a biologically active amyloidhttps://t.co/3Bm7hyHDOC pic.twitter.com/SrFnxCdfGu
Phase II trial of nusinersen to treat infantile-onset spinal muscular atrophy produces encouraging results https://t.co/Y4AZkMQlxi
— Nat Rev Neurology (@NatRevNeurol) December 7, 2016
Very nice Nature piece on bispecifics. h/t @endpts $XNCR $MGNX $MRUS $AMGN https://t.co/qPwMc6atcb
— Brad Loncar (@bradloncar) December 9, 2016
Important --> First “Off switch” for #CRISPR/Cas9 gene editing discoveredhttps://t.co/fwsX0leI7dhttps://t.co/11CI3Hq3UJ$EDIT $NTLA $CRSP pic.twitter.com/ywF8Hd6dZ5
— Andy Biotech (@AndyBiotech) December 10, 2016
2 new, good papers on reproducibility in science https://t.co/Nub90fluzF@sciencemagazine https://t.co/8B6SF5edyB pic.twitter.com/m6MnNE4URd
— Eric Topol (@EricTopol) December 10, 2016
Paper w disturbing implications 4 #immunotherapy drug devlp - a highly adaptive tumor mutanome (what neoantigens?)https://t.co/k8jtW8OVd5
— Paul D. Rennert (@PDRennert) January 7, 2017